브레인스톰 셀 테라퓨틱스(BCLI)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.98 (+0.10%), 시가총액 $0.01B, 52주 최저~최고 $0.48 ~ $1.31.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the t
브레인스톰 셀 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
브레인스톰 셀 테라퓨틱스의 현재 주가는 $0.98 (+0.10%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
브레인스톰 셀 테라퓨틱스의 시가총액은 약 $0.01B입니다.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The compa